UNSPSC 51384629: Oxyphenbutazone anhydrous

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H20N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A7D84513GV, chemically known as (+/-)-oxyphenbutazone anhydrous, but more generally known as oxyphenbutazone anhydrous, which bears US NIH Compound Identifier 4641. European Medicines Agency schedules oxyphenbutazone anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09572MIG.

Most nations, for tariff purposes, schedule oxyphenbutazone anhydrous under HS 29331990. Oxyphenbutazone anhydrous bears US NLM identifiers UMLS ID C2698680 and NCI Concept Code C74597. SMILES: CCCCC1C(=O)N(N(C1=O)C2CCC(CC2)O)C3CCCCC3.

UNSPSC 51384629 Oxyphenbutazone anhydrous is a Commodity code that shows minimal alignment with recent state and local procurement activity. The three recent opportunities tagged to this code—naloxone and drug deactivation systems procurement, a direct-to-manufacturer pharmacy initiative RFI, and a multi-state generic pharmaceuticals and OTC products cooperative purchasing agreement—do not represent oxyphenbutazone anhydrous procurement. Oxyphenbutazone is a nonsteroidal anti-inflammatory drug with limited modern clinical use, yet the tagged solicitations address emergency response naloxone systems, pharmacy benefit program modernization, and broad-based generic pharmaceutical distribution through wholesalers. The code appears to reflect a classification mismatch rather than active state and local demand for this specific pharmaceutical ingredient.

The issuing bodies in the recent opportunities span state health and human services agencies and multi-state cooperative purchasing vehicles: Seminole County, Florida (pursuing naloxone and drug deactivation systems via IFB 60459723LAS, due July 26, 2023); the Texas Health and Human Services Commission (issuing RFI HHS0017013 on April 3, 2026, to explore direct-to-manufacturer prescription programs); and the Minnesota Multistate Cooperative Purchasing Alliance (administering an RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, due March 26, 2026, with awards effective July 1, 2026). Geographic activity centers on Texas, Minnesota (serving multiple state and local participants including Oregon), and Florida. The code itself shows no current demand for oxyphenbutazone anhydrous at the state and local level; procurement professionals should verify code assignment before pursuing opportunities listed under this taxonomy entry.